skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Selective cytotoxicity of /sup 125/I-labeled monoclonal antibody T101 in human malignant T cell lines

Journal Article · · Blood; (United States)
OSTI ID:5843349

The radiolabeled anti-T cell antibody T/sup 101/ can be used for specific tumor localization, but unlabeled T/sup 101/ produces limited cytotoxicity in patients. We studied the in vitro cytotoxic effects of T/sup 101/ labeled with /sup 125/I, a radionuclide known for its short-range, high-linear-energy electrons. We showed that /sup 125/I-T/sup 101/ could be readily prepared at high specific activity with high immunoreactivity. Human malignant T cell lines HUT 102, MOLT-4, and HUT 78 were found to differ in the number of T65 determinants (the antigen recognized by T/sup 101/) and the sensitivity to external x-ray radiation, which were of significance for the cytotoxicity of /sup 125/I-T/sup 101/ in vitro. The cytotoxic effects of /sup 125/I-T/sup 101/ were also found to be dose dependent and increased with exposure time under frozen conditions. As controls, unlabeled T/sup 101/ had no cytotoxic effect, while free Na /sup 125/I or the /sup 125/I-labeled irrelevant antibody 9.2.27 exerted minor cytotoxicity. In HUT 102 and MOLT-4, more than 3 logs cell killing was achieved within four weeks. Because considerable cytotoxicity was demonstrated in vitro by /sup 125/I-T/sup 101/ on T65-positive malignant cells, and because low-dose /sup 111/In-T/sup 101/ can be used successfully for tumor localization, future trials using /sup 125/I-T/sup 101/ at high specific radioactivity may improve therapeutic results in patients with T65-positive malignancies.

Research Organization:
National Cancer Institute-Navy Medical Oncology, Bethesda, MD
OSTI ID:
5843349
Journal Information:
Blood; (United States), Vol. 2
Country of Publication:
United States
Language:
English